SCHEMBL2335264

SCHEMBL2335264

COc1cnc(Cl)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30971909 1.00 — —
SCHEMBL3138241 0.84 SIRT6 (0.56) —
SCHEMBL22518716 0.76 MAPT (0.40) —
SCHEMBL21807894 0.76 PLAU (0.40) —
SCHEMBL22518721 0.75 ALDH1A1 (0.39) —
SCHEMBL15577926 0.74 PLAU (0.33) —
SCHEMBL933680 0.74 — —
SCHEMBL18994460 0.73 IDO1 (0.34) —
SCHEMBL18994454 0.73 GABRP (0.38) —
SCHEMBL27932250 0.73 ALDH1A1 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101687860-A Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ASTRAZENECA AB 2010-03-31 — — CN claimed
US-20250326754-A1 DNA-PK Inhibitor Compounds and Uses Thereof ADMARE THERAPEUTICS SOC (CA) 2025-10-23 — — US disclosed
US-20250230172-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-07-17 — — US disclosed
US-12275728-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-04-15 — — US disclosed
EP-4522620-A1 DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF Admare Therapeutics Society (CA) 2025-03-19 — — EP disclosed
US-20250074895-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME BLUEPRINT MEDICINES CORPORATION 2025-03-06 — — US disclosed
US-12180205-B2 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2024-12-31 — — US disclosed
US-20240308995-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2024-09-19 — — US disclosed
EP-4416152-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-08-21 — — EP disclosed
CN-113166137-B O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranoside enzyme inhibitors 比奥根MA公司 2024-08-16 — — CN disclosed
US-20110245227-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 — — US disclosed
EP-2170864-B1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2011-09-14 — — EP disclosed
US-8003796-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-23 — — US disclosed
CN-101001851-B Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) ASTELLAS PHARMA INC 2011-04-20 — — CN disclosed
CN-101801957-A Pyridone GPR 119 g protein-coupled receptor agonists BRISTOL MYERS SQUIBB CO 2010-08-11 — — CN disclosed
EP-2170864-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2010-04-07 — — EP disclosed
CN-101687860-A Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ASTRAZENECA AB 2010-03-31 — — CN disclosed
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-22 — — US disclosed
WO-2009012275-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-22 — — WO disclosed
CN-101001851-A Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) ASTELLAS PHARMA INC (JP) 2007-07-18 — — CN disclosed
Send feedback